B Fautrel

Summary

Country: France

Publications

  1. ncbi Economic benefits of optimizing anchor therapy for rheumatoid arthritis
    Bruno Fautrel
    Department of Rheumatology, University of Pierre and Marie Curie Paris 6, AP HP, Pitie Salpetriere University Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Rheumatology (Oxford) 51:iv21-6. 2012
  2. ncbi Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data
    Bruno Fautrel
    Department of Rheumatology, Université Pierre et Marie Curie Sorbonne Universités, AP HP Assistance Publique Hôpitaux de Paris, Pitie Salpetriere Hospital, Paris, France
    Ann Rheum Dis 71:386-9. 2012
  3. ncbi Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
    Michel De Bandt
    Centre hospitalier d Aulnay sous Bois, Service de Rhumatologie, Boulevard Ballanger, Aulnay sous Bois F 93600, France
    Arthritis Res Ther 11:R157. 2009
  4. ncbi Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial
    B Fautrel
    APHP, Groupe Hospitalier Pitie Salpetriere, Service of Rhumatologie, Paris, France
    Ann Rheum Dis 69:424-7. 2010
  5. ncbi Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences
    Bruno Fautrel
    Department of Rheumatology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Arthritis Rheum 61:425-34. 2009
  6. ncbi Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort
    Bruno Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Rheumatology (Oxford) 49:147-55. 2010
  7. ncbi Adult-onset Still disease
    Bruno Fautrel
    Pierre and Marie Curie Paris VI University Paris Universitas, Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75651 Paris, Cedex 13, France
    Best Pract Res Clin Rheumatol 22:773-92. 2008
  8. ncbi Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis
    Bruno Fautrel
    Pierre and Marie Curie University Paris VI, UFR de Medecine, France
    Joint Bone Spine 74:627-37. 2007
  9. ncbi [Chronic inflammatory disorders and reproduction]
    B Fautrel
    Service de Rhumatologie, Groupe Hospitalier de la Pitié Salpêtrière, Universite Paris VI Pierre et Marie Curie, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Gynecol Obstet Fertil 35:848-52. 2007
  10. ncbi Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis
    Bruno Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, UFR de Medecine, Universite Pierre et Marie Curie Paris VI, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Joint Bone Spine 73:433-41. 2006

Collaborators

Detail Information

Publications59

  1. ncbi Economic benefits of optimizing anchor therapy for rheumatoid arthritis
    Bruno Fautrel
    Department of Rheumatology, University of Pierre and Marie Curie Paris 6, AP HP, Pitie Salpetriere University Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Rheumatology (Oxford) 51:iv21-6. 2012
    ....
  2. ncbi Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data
    Bruno Fautrel
    Department of Rheumatology, Université Pierre et Marie Curie Sorbonne Universités, AP HP Assistance Publique Hôpitaux de Paris, Pitie Salpetriere Hospital, Paris, France
    Ann Rheum Dis 71:386-9. 2012
    ..In 2010, new classification criteria for rheumatoid arthritis (RA) were developed...
  3. ncbi Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
    Michel De Bandt
    Centre hospitalier d Aulnay sous Bois, Service de Rhumatologie, Boulevard Ballanger, Aulnay sous Bois F 93600, France
    Arthritis Res Ther 11:R157. 2009
    ....
  4. ncbi Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial
    B Fautrel
    APHP, Groupe Hospitalier Pitie Salpetriere, Service of Rhumatologie, Paris, France
    Ann Rheum Dis 69:424-7. 2010
    ..To determine the incremental cost-effectiveness ratios (ICERs) of two therapeutic regimens of infliximab for ankylosing spondylitis (AS)...
  5. ncbi Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences
    Bruno Fautrel
    Department of Rheumatology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Arthritis Rheum 61:425-34. 2009
    ..To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA)...
  6. ncbi Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort
    Bruno Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Rheumatology (Oxford) 49:147-55. 2010
    ....
  7. ncbi Adult-onset Still disease
    Bruno Fautrel
    Pierre and Marie Curie Paris VI University Paris Universitas, Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75651 Paris, Cedex 13, France
    Best Pract Res Clin Rheumatol 22:773-92. 2008
    ..For refractory disease, biological therapy with agents blocking interleukin-1 (anakinra) and then those blocking interleukin-6 (tocilizumab) seem the most promising...
  8. ncbi Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis
    Bruno Fautrel
    Pierre and Marie Curie University Paris VI, UFR de Medecine, France
    Joint Bone Spine 74:627-37. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of TNFalpha antagonists for treating patients with rheumatoid arthritis (RA)...
  9. ncbi [Chronic inflammatory disorders and reproduction]
    B Fautrel
    Service de Rhumatologie, Groupe Hospitalier de la Pitié Salpêtrière, Universite Paris VI Pierre et Marie Curie, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Gynecol Obstet Fertil 35:848-52. 2007
    ..Moreover, some treatments may directly affect fertility, which may justify specific managements in order to preserve gonadic functions...
  10. ncbi Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis
    Bruno Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, UFR de Medecine, Universite Pierre et Marie Curie Paris VI, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Joint Bone Spine 73:433-41. 2006
    ..To develop recommendations for TNFalpha-antagonist therapy in patients with rheumatoid arthritis (RA) seen in everyday practice, under the aegis of the French Society for Rheumatology...
  11. ncbi Sensitivity and specificity of ultrasonography in early diagnosis of metatarsal bone stress fractures: a pilot study of 37 patients
    Frederic Banal
    J Rheumatol 36:1715-9. 2009
    ..Our objective was to evaluate sensitivity and specificity of US versus dedicated MRI (0.2 Tesla), taken as the gold standard, in early diagnosis of metatarsal bone stress fractures...
  12. ncbi Economic consequences and potential benefits
    Bruno Fautrel
    Paris 6 Pierre et Marie Curie University, APHP Pitie Salpetriere Hospital, Department of Rheumatology, France
    Best Pract Res Clin Rheumatol 25:607-24. 2011
    ....
  13. ncbi Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology
    X Le Loet
    Department of Rheumatology, Rouen University Hospital, France
    Ann Rheum Dis 65:45-50. 2006
    ..To elaborate a clinical practice decision tree for the choice of the first disease modifying antirheumatic drug (DMARD) for untreated rheumatoid arthritis of less than six months' duration...
  14. ncbi Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology
    B Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Rheumatology (Oxford) 47:1698-703. 2008
    ..Objectives of the PRISME II survey were to assess and compare eligibility for anti-TNF-alpha therapy of RA patients consulting their usual rheumatologist according to (i) the SFR and BSR guidelines and (ii) the rheumatologist's opinion...
  15. ncbi Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort
    M Soubrier
    Department of Rheumatology, Hopital G Montpied, 63003 Clermont Ferrand, France
    Ann Rheum Dis 70:611-5. 2011
    ....
  16. ncbi Bone marrow oedema predicts structural progression in a 1-year follow-up of 85 patients with RA in remission or with low disease activity with low-field MRI
    F Gandjbakhch
    Department of Rheumatology, Pitie Salpetriere Hospital, APHP, Université Paris UPMC, France
    Ann Rheum Dis 70:2159-62. 2011
    ..To identify the predictive factors of MRI-determined structural progression in patients with rheumatoid arthritis (RA) in remission or with low disease activity (LDA)...
  17. ncbi Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study
    M De Bandt
    Rheumatology Unit, Bichat Teaching Hospital, Paris, France
    J Rheumatol 26:91-6. 1999
    ..To investigate whether serial anticardiolipin determination contributes to the clinical management of patients with systemic lupus erythematosus (SLE) with no previous sign of the antiphospholipid syndrome (APS)...
  18. ncbi Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France
    Bruno Fautrel
    Department of Rheumatology, Groupe Hospitalier Pitie Salpetriere, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Joint Bone Spine 72:550-6. 2005
    ..Moreover, we must add the costs associated with their administration to the purchase price. Variations in medical practices may be the source of substantial variations in these costs...
  19. ncbi Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides
    B Terrier
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Ann Rheum Dis 68:1564-71. 2009
    ..To evaluate the relevance of monitoring antimyeloperoxidase antibody levels in the management of antimyeloperoxidase-associated vasculitides...
  20. ncbi Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases
    B Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Ann Rheum Dis 64:262-6. 2005
    ..Consensus is lacking on treatment for corticosteroid resistant adult onset Still's disease (ASD)...
  21. ncbi Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
    D Salmon-Ceron
    Service de Rhumatologie, Hopital Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre
    Ann Rheum Dis 70:616-23. 2011
    ..Anti-tumour necrosis factor (TNF) therapy may be associated with opportunistic infections (OIs)...
  22. ncbi Long-term return to work after a functional restoration program for chronic low-back pain patients: a prospective study
    Cécile Poulain
    Department of Rheumatology, University Pierre et Marie Curie Paris VI, Groupe Hospitalier Pitie Salpetriere, 83 Boulevard de l hopital, 75651, Paris Cedex 13, France
    Eur Spine J 19:1153-61. 2010
    ..FRP show positive results in terms of return to work for chronic LBP patients with prolonged work absenteeism. Efforts should be made to propose such programs at an earlier stage of the disease...
  23. ncbi Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review
    Adeline Ruyssen-Witrand
    Service de Rhumatologie B, Hopital Cochin, AP HP, université Paris V René Descartes, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Joint Bone Spine 77:246-51. 2010
    ..To study the association between infection risk and low-dose corticosteroids (LD-CT, defined as a daily dose <10mg/day of prednisone) in rheumatoid arthritis (RA)...
  24. ncbi Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy
    Jacques-Eric Gottenberg
    , Paris, France
    Arthritis Rheum 48:2019-24. 2003
    ....
  25. ncbi Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy
    Olivier Meyer
    Department of Rheumatology, AP HP, Bichat Paris 7 University Hospital, CHU Bichat, 46 rue Henri Huchard, 75018 Paris, France
    Joint Bone Spine 74:73-8. 2007
    ..The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA...
  26. ncbi Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    Maxime Breban
    Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne Billancourt, France
    Arthritis Rheum 58:88-97. 2008
    ..This study was undertaken to compare the efficacy of continuous treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Methotrexate (MTX) in combination with infliximab was also tested...
  27. ncbi The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort
    Mathilde Benhamou
    Department of Rheumatology, University of Paris VI, Pitie Salpetriere Hospital, Paris, France
    J Rheumatol 36:934-42. 2009
    ....
  28. ncbi TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, 147, Bd Baille, 13005 Marseille, France
    Joint Bone Spine 73:547-53. 2006
    ..To develop recommendations for TNFalpha antagonist therapy in patients with spondyloarthropathies...
  29. ncbi Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease
    B Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, Paris, France
    J Rheumatol 28:322-9. 2001
    ..To determine the usefulness of serum ferritin and glycosylated ferritin (GF) levels in diagnosing adult onset Still's disease (AOSD)...
  30. ncbi [Indications of anakinra]
    Karine Chauffier
    Service de Rhumatologie, GH Pitié Salpétrière, AP HP, Universite Paris 6 Pierre et Marie Curie, UFR de Medecine, Site Pitié Salpêtrière, F 75013 Paris, France
    Presse Med 38:799-807. 2009
    ..Anakinra could be an interesting drug for the treatment of neutrophilic dermatosis or relapsing chondritis, refractory to conventional agents. Injection site reactions and infections are the 2 main anakinra-related side effects...
  31. ncbi Benefits of ultrasonography in the management of early arthritis: a cross-sectional study of baseline data from the ESPOIR cohort
    Thomas Funck-Brentano
    Department of Rheumatology, Academic Hospital Pitie Salpétrière, Paris, France
    Rheumatology (Oxford) 48:1515-9. 2009
    ..To assess ultrasonography's (US) performance to detect the structural damage in the initial evaluation of early arthritis (EA) using the Etude et Suivides Polyarthrites Indifférenciées Récentes (ESPOIR) cohort...
  32. ncbi Relapse of Wegener's granulomatosis. Concerning a case after 20 years of remission
    V Foltz
    Rheumatology Unit, , Paris, France
    Joint Bone Spine 68:262-6. 2001
    ..Other drugs are studied to identify more efficient therapy, able to both induce remission and prevent relapses, but reliable data are still missing to determine the best therapeutic regimen...
  33. ncbi Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature
    L Levy
    Department of Rheumatology, University Hospital Pellegrin, Bordeaux, France
    Clin Exp Rheumatol 26:673-9. 2008
    ..We conducted a meta-analysis to evaluate more accurately the incidence of cardiovascular events, and the excess of cardiovascular risk in a population of RA patients...
  34. ncbi Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Bruno Fautrel
    Service de Rhumatologie, , Paris, France
    Joint Bone Spine 72:163-70. 2005
    ..7% to 100%. CONCLUSION: Recommendations about educating and informing patients with RA in everyday practice were developed. They should increase practice uniformity and ultimately optimize the management of patients with RA...
  35. ncbi [Focus on biological agents in rheumatoid arthritis: newer treatments and therapeutic strategies]
    Marianne Fanet-Goguet
    Service de Rhumatologie, , Paris, France
    Therapie 59:451-61. 2004
    ..This paper reviews recent data on biological therapies for rheumatoid arthritis: tolerance and their ability to modify the course of disease and prevent radiological damage...
  36. ncbi Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective
    Bruno Fautrel
    Department of Rheumatology, Hospital Pitié Salpêtrière, 83 bd de l hopital, 75013 Paris, France
    J Rheumatol 32:443-53. 2005
    ..The validity of the survey was explored by studying the association between WTP and variables thought to be associated with WTP and randomly-varied variables of the survey materials...
  37. ncbi Tocilizumab: therapy and safety management
    Thao Pham
    Service de Rhumatologie, CHU Conception, Marseille, France
    Joint Bone Spine 77:S3-100. 2010
    ..To develop fact sheets about tocilizumab, in order to assist physicians in the management of patients with inflammatory joint disease...
  38. ncbi Amyloid arthropathy in the course of multiple myeloma
    Bruno Fautrel
    Rheumatology Institute, Hĵpital Cochin, Paris, France
    J Rheumatol 29:1473-81. 2002
    ..CONCLUSION: This series provides reliable information on amyloid arthropathy, especially regarding functional effects, anatomical lesions on MRI, and therapeutic options...
  39. ncbi Abatacept therapy and safety management
    Thao Pham
    Service de Rhumatologie, CHU Conception, Marseille, France
    Joint Bone Spine 76:S3-S55. 2009
    ..To elaborate a how-to-use abatacept material intended to help physicians in the management of patients with inflammatory diseases treated with this drug in routine practice...
  40. ncbi Post-lumbar puncture arachnoiditis. The need for directed questioning
    Fabien Etchepare
    Department of Rheumatology, Hospital Pitié Salpêtrière, 47 83 boulevard de l Hopital, 75013 Paris, France
    Joint Bone Spine 72:180-2. 2005
    ..Sequelae of arachnoiditis are difficult to diagnosis. When MRI or myelography suggests it as a possibility, precise directed questioning is necessary to seek a history, albeit distant, of spinal or meningeal events...
  41. ncbi Diagnosis of synovitis by ultrasonography in RA: a one-year experience is enough for reliability on static images
    Carole Rosenberg
    Rheumatology Unit, La Pitie Salpetriere Hospital, 49 bld de l Hôpital, 75013 Paris, France
    Joint Bone Spine 76:35-8. 2009
    ..To evaluate the inter- and intra-observer agreement of ultrasonographic metacarpophalangeal joint static images in patients with rheumatoid arthritis by two investigators with different ultrasonographic experience...
  42. ncbi Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 72:222-8. 2005
    ..Because they constitute an objective foundation built by consensus among experts, should improve the uniformity and quality of care provided to RA patients in everyday practice...
  43. ncbi Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Laure Gossec
    Rheumatology Department, Cochin Teaching Hospital, Paris, France
    Joint Bone Spine 72:229-34. 2005
    ..They should help to improve practice uniformity and, ultimately, to improve the management of RA...
  44. ncbi Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France
    Christian H Roux
    Department of Rheumatology, University Hospital, Nice, France
    J Rheumatol 34:117-22. 2007
    ..To determine geographical variation in the prevalence of rheumatoid arthritis (RA) and spondyloarthropathies (SpA) in France...
  45. ncbi Impact of osteoarthritis: results of a nationwide survey of 10,000 patients consulting for OA
    Bruno Fautrel
    Department of Rheumatology, Hospital Pitié Salpêtrière, Paris, France
    Joint Bone Spine 72:235-40. 2005
    ..The clinical burden of osteoarthritis (OA) is difficult to assess because of the substantial variability between patients...
  46. ncbi Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method
    Bruno Fautrel
    Department of Rheumatology, University of Paris VI Pierre et Marie Curie, Hospital Pitié Salpêtrière, Paris, France
    Med Decis Making 27:138-50. 2007
    ..Individuals' valuation of changes in health states in monetary terms have been measured by examining changes in the direct and indirect costs of disease and by the willingness-to-pay (WTP) methodology...
  47. ncbi Back problems in Parkinson's disease: an underestimated problem
    Fabien Etchepare
    Department of Rheumatology, Pitie Salpetriere Hospital, Paris, France
    Joint Bone Spine 73:298-302. 2006
    ..Cross-sectional survey...
  48. ncbi A pilot study on the recovery from paresis after lumbar disc herniation
    Genevieve Dubourg
    Service de Rhumatologie, CHU Pitie Salpetriere, Paris, France
    Spine (Phila Pa 1976) 27:1426-31; discussion 1431. 2002
    ..Although the existence of a motor defect in discogenic sciatica is a sign of severity, the literature does not provide evidence for an immediate requirement for surgery...
  49. ncbi Use of complementary and alternative therapies by patients self-reporting arthritis or rheumatism: results from a nationwide canadian survey
    Bruno Fautrel
    Department of Rheumatology, Hospital Pitié Salpêtrière, Paris, France
    J Rheumatol 29:2435-41. 2002
    ..Arthritis or rheumatism (A/R) often leads patients to experiment with complementary and alternative medicine (CAM); we investigated the factors associated with use of CAM...
  50. ncbi Use of complementary and alternative therapies by patients with self-reported chronic back pain: a nationwide survey in Canada
    Violaine Foltz
    Rheumatology Department, Pitié Salpêtrière Teaching Hospital, 49 83 Bd de l Hôpital, 75013 Paris, France
    Joint Bone Spine 72:571-7. 2005
    ..Complementary and alternative medicine (CAM) is gaining popularity among patients with chronic back pain. We looked for factors associated with CAM use...
  51. ncbi Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update
    Thao Pham
    Rheumatology Department, La Conception Teaching Hospital, 147 Boulevard Baille, 13005 Marseille, France
    Joint Bone Spine 74:638-46. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of tumor necrosis factor alpha (TNFalpha) antagonists for treating patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA)...
  52. ncbi Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al
    Bruno Fautrel
    Arthritis Rheum 46:1408-9; author reply 1409. 2002
  53. ncbi Costs of workups for the diagnosis of early arthritis: results of a nationwide survey
    Bruno Fautrel
    , Paris and School of Public Health, Nancy, France. bruno.fautrel.psl.ap-hop-paris.fr
    Arthritis Rheum 51:507-12. 2004
    ..This observation and the great variability observed in physicians' practices point out the need for consensus on the appropriate workups for these patients...
  54. ncbi Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
    Michel De Bandt
    Rheumatology Department, Hopital Robert Ballanger, Aulnay sous Bois, France
    Arthritis Res Ther 7:R545-51. 2005
    ..19% with infliximab and 7/3800 = 0.18% with etanercept. Clinicians should be aware that lupus syndromes with systemic manifestations may occur in patients under anti-TNF alpha treatment...
  55. ncbi Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR)
    Thao Pham
    Service de Rhumatologie Sud, , 147 Bd Baille, 13005 Marseille
    Joint Bone Spine 72:S1-58. 2005
  56. ncbi The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients
    Bernard Combe
    University Hospital, Montpellier, France
    Joint Bone Spine 74:440-5. 2007
    ....
  57. ncbi Laboratory and imaging studies used by French rheumatologists to evaluate patients with early arthritis
    Alain Saraux
    Rheumatology Units of the Brest, Dijon, Paris La Pitiè, Lille, and Marseille La Timone Teaching Hospitals, France
    J Rheumatol 33:897-902. 2006
    ..To conduct a practice survey of laboratory and imaging studies used by French rheumatologists to identify the cause of recent-onset arthritis...
  58. ncbi Ferritin levels in adult Still's disease: any sugar?
    Bruno Fautrel
    Joint Bone Spine 69:355-7. 2002
  59. ncbi Recommendations for the prevention of osteoporosis and fragility fractures. International comparison and synthesis
    Michel Rossignol
    McGill University
    Int J Technol Assess Health Care 18:597-610. 2002
    ..A second compromise would be to recognize the complementary roles of public health and clinical professionals toward the common objective of preventing fragility fractures...